Wells Fargo analyst Joseph O’Dea raised the firm’s price target on Emerson (EMR) to $160 from $145 and keeps an Equal Weight rating on the shares. The firm viewed orders as the KPI this quarter, with a low double-digit order scenario adding shortfall risk to the second-half organic revenue guide of mid-single-digit growth, while a mid-single-digit order scenario would support second-half organic revenue. High-single-digit orders are clearly a positive outcome, as the firm’s EPS estimate moves up 1%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR:
- Sell Rating Maintained Amid Growth Headwinds, Unreliable Order Signals, and Second-Half Execution Risks
- Emerson reports Q1 adjusted EPS $1.46, consensus $1.41
- Emerson sees FY26 adjusted EPS $6.40-$6.55, consensus $6.48
- Emerson sees Q2 adjusted EPS $1.50-$1.55, consensus $1.56
- Is EMR a Buy, Before Earnings?
